BIO-key International has closed a new senior secured note with Streeterville Capital that is small in size but unusually muscular in structure for a biometrics vendor. The filing shows a principal amount of $1.13 million carrying nine percent annual interest with an original issue discount of $125,000 and $5,000 in transaction costs, leaving $1 million of cash proceeds. The note matures eighteen months after funding.
The unusual part is the collateral package and the repayment mechanics. BIO-key signed both a blanket security agreement and a separate intellectual property security agreement. The IP schedule lists specific U.S. patents covering biometric recognition methods, mobile biometric workflows, and authentication techniques. In addition, the blanket security agreement says the collateral is intended to comprise any and all of the company’s assets, now owned or later acquired, with only limited exclusions. Taken together, the lender has rights against operating assets and the underlying biometric IP if the company defaults. That is more intrusive than a typical small corporate working-capital line, which may be secured by receivables and equipment but not always by enumerated patents.
The note also builds in cash-flow discipline after a six-month grace period. Starting six months after funding, Streeterville can require monthly redemptions up to $135,000. If BIO-key has not reduced the outstanding balance by at least that much by month end, it must make up the difference in cash or the balance steps up by one percent. Every pay-down, whether voluntary or mandatory, carries a seven percent exit fee. These mechanics are common in specialty finance, but they are still tougher than what many software companies see in ordinary bank facilities.
Two other details are worth noting for readers who follow identity vendors’ capital structures. First, every future financing or warrant exercise triggers a mandatory prepayment equal to the lesser of forty percent of the new money raised or the remaining balance on the note. That covenant can pull forward cash outflows if the company raises follow-on funds. Second, default remedies include a potential interest step-up to as high as twenty-two percent per year, subject to legal caps, along with IP enforcement rights set out in the security documents. The governing law is Utah and disputes are subject to arbitration under the purchase agreement.
There is also a downstream reach on the collateral: BIO-key’s PistolStar subsidiary provided a separate guaranty. Readers may recall PistolStar as the company behind the PortalGuard access platform that BIO-key acquired and integrated. A subsidiary guaranty is not unheard of, but pairing it with a patent-by-patent IP pledge underscores how central the identity portfolio is to this financing.
For context, BIO-key has used Streeterville before. The 2025 note’s terms rhyme with a June 2024 Streeterville facility, including the eighteen-month tenor, nine percent interest, and monthly redemption construct. What is new this time is the fresh collateralization of an updated patent schedule and the explicit all-assets language in the security agreement, which makes the package read closer to a comprehensive lien plus IP assignment than a light-touch receivables pledge. That is why this filing is worth flagging even though the dollar amount is modest.
The takeaway: This is a tightly structured specialty-finance note secured by virtually everything at BIO-key including named biometric patents, plus monthly redemption pressure and mandatory prepayment on future financings. It is not a commentary on BIO-key’s health on its own. It is a reminder that in identity markets, intellectual property is often the first line of collateral and filings like this are where that becomes visible.
Source: BIO-key Form 8-K exhibits
—
By Cass Kennedy
